Literature DB >> 14977779

Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis.

C C Murphy1, L Duncan, J V Forrester, A D Dick.   

Abstract

AIM: To investigate peripheral blood lymphocyte phenotype in patients with intermediate uveitis using CD69, chemokine receptor, and cytokine expression.
METHODS: Peripheral blood lymphocytes of 18 patients with idiopathic intermediate uveitis and 6 patients with presumed sarcoid intermediate uveitis were evaluated for CD4(+) T cell expression of CD69, CCR4, CCR5, CXCR3 and the intracellular cytokines IFNgamma, TNFalpha, and interleukin (IL)-10 by flow cytometry, and for IL-2, IL-4, IL-5, IL-10, IFNgamma, and TNFalpha production following unstimulated and activated culture using cytokine bead array and compared with healthy control subjects.
RESULTS: The expression of CD69 and TNFalpha by peripheral blood CD4(+) lymphocytes of patients with idiopathic intermediate uveitis and presumed sarcoid intermediate uveitis was significantly higher than control subjects (p = 0.002 and p<0.05, respectively). The ratios of the concentrations of IL-2:IL-5 and IFNgamma:IL-5 in supernatants of activated peripheral blood lymphocyte cultures were significantly higher in patients with presumed sarcoid intermediate uveitis than control subjects.
CONCLUSIONS: This study implicates TNFalpha in the pathogenesis of intermediate uveitis, highlighting the potential role of anti-TNF treatments for this disease. Studies of Th1:Th2 cytokine ratios suggested polarisation of the immune response towards Th1 in presumed sarcoid intermediate uveitis despite clinically quiescent systemic disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14977779      PMCID: PMC1772058          DOI: 10.1136/bjo.2003.028506

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  30 in total

1.  Soluble ICAM-1 serum levels in patients with intermediate uveitis.

Authors:  A M Klok; L Luyendijk; M J Zaal; A Rothova; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

2.  Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis.

Authors:  M Möllers; S P Aries; D Drömann; B Mascher; J Braun; K Dalhoff
Journal:  Thorax       Date:  2001-06       Impact factor: 9.139

3.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

4.  CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis.

Authors:  D J Kilmartin; Z J Fletcher; J A Almeida; J Liversidge; J V Forrester; A D Dick
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-05       Impact factor: 4.799

Review 5.  Regulation of autoimmunity by proinflammatory cytokines.

Authors:  A P Cope
Journal:  Curr Opin Immunol       Date:  1998-12       Impact factor: 7.486

6.  Etanercept therapy in children with treatment-resistant uveitis.

Authors:  A Reiff; S Takei; S Sadeghi; A Stout; B Shaham; B Bernstein; K Gallagher; T Stout
Journal:  Arthritis Rheum       Date:  2001-06

7.  Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics.

Authors:  E B Cook; J L Stahl; L Lowe; R Chen; E Morgan; J Wilson; R Varro; A Chan; F M Graziano; N P Barney
Journal:  J Immunol Methods       Date:  2001-08-01       Impact factor: 2.303

8.  Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis.

Authors:  M S Lacomba; C M Martin; R R Chamond; J M Galera; M Omar; E C Estevez
Journal:  Arch Ophthalmol       Date:  2000-06

9.  TH1/TH2 and TC1/TC2 profiles in peripheral blood and bronchoalveolar lavage fluid cells in pulmonary sarcoidosis.

Authors:  N Inui; K Chida; T Suda; H Nakamura
Journal:  J Allergy Clin Immunol       Date:  2001-02       Impact factor: 10.793

10.  Oligoclonal activation of CD4+ T lymphocytes in posterior uveitis.

Authors:  E J Feron; V L Calder; S L Lightman
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

View more
  13 in total

Review 1.  Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

Authors:  Kenneth G-J Ooi; Grazyna Galatowicz; Virginia L Calder; Susan L Lightman
Journal:  Clin Med Res       Date:  2006-12

Review 2.  Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.

Authors:  R W J Lee; A D Dick
Journal:  Eye (Lond)       Date:  2011-09-30       Impact factor: 3.775

3.  Retinal S-antigen Th1 cell epitope mapping in patients with Behcet's disease.

Authors:  Changlin Zhao; Peizeng Yang; Hao He; Xiaomin Lin; Liping Du; Hongyan Zhou; Aize Kijlstra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-29       Impact factor: 3.117

4.  Pars planitis is associated with an increased frequency of effector-memory CD57+ T cells.

Authors:  Miguel Pedroza-Seres; Marisela Linares; Stephanie Voorduin; Rojas-Ramos Enrique; Ricardo Lascurain; Yonathan Garfias; Maria Carmen Jimenez-Martinez
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

5.  LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells.

Authors:  Matthew A Cunningham; Bobbie Ann Austin; Zhuqing Li; Baoying Liu; Steven Yeh; Chi-Chao Chan; Eddy Anglade; Poonam Velagaleti; Robert B Nussenblatt
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-15       Impact factor: 4.799

6.  Clinical characteristics and treatment of pars planitis: an adalimumab experience.

Authors:  Huseyin Baran Ozdemir; Pinar Cakar Ozdal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-27       Impact factor: 3.117

7.  Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats.

Authors:  Cheng-bo Fang; De-xi Zhou; Shu-xiang Zhan; Yong He; Zhen Lin; Cheng Huang; Jun Li
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

8.  Intraocular and serum cytokine profiles in patients with intermediate uveitis.

Authors:  Natasa Vidovic Valentincic; Jolanda D F de Groot-Mijnes; Aleksandra Kraut; Peter Korosec; Marko Hawlina; Aniki Rothova
Journal:  Mol Vis       Date:  2011-07-20       Impact factor: 2.367

Review 9.  Immunopathogenic Background of Pars Planitis.

Authors:  Joanna Przeździecka-Dołyk; Agnieszka Węgrzyn; Anna Turno-Kręcicka; Marta Misiuk-Hojło
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-10-05       Impact factor: 4.291

10.  Imbalance in PB IL-17-Secreting and Regulatory Cells in Pars Planitis Is Associated with Dysregulation of IFN-γ-Secreting Cells, Especially in Patients with Clinical Complications.

Authors:  Agata Kosmaczewska; Joanna Przeździecka-Dołyk; Anna Turno-Kręcicka; Lidia Ciszak; Aleksandra Szteblich; Agnieszka Węgrzyn; Irena Frydecka; Marta Misiuk-Hojło
Journal:  Mediators Inflamm       Date:  2020-07-31       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.